Cadila set to foray into US generics market;gets US FDA approval for two drugs

摘要

The Ahmedabad-based Zydus Cadila Healthcare Ltd.has received US-FDA approval for two drugs:the anti-hypertensive drug,Atenolol,and an anti-infective drug,Clindamycin.The company is planning to launch both the drugs by the end of May.Apart from these two drugs,the group expects to launch six more drugs this year,subject to approvals of the regulatory body.The total US market for these two drugs is estimated at US87-mn.The company is at present strengthening its position in the US market through its wholly owned subsidiary,Zydus Pharmaceuticals Inc.